Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12384536 | 1.00 | MDM2 (0.35) | MDM2GAAL3MBTL1ROCK2ROCK1 | |
| SCHEMBL409484 | 1.00 | MDM2 (0.35) | MDM2GAAL3MBTL1ROCK2ROCK1 | |
| SCHEMBL18458286 | 0.86 | MDM2 (0.41) | MDM2GAAL3MBTL1IRAK4DRD2 | |
| SCHEMBL16171239 | 0.86 | MDM2 (0.41) | MDM2GAAL3MBTL1IRAK4DRD2 | |
| SCHEMBL2600363 | 0.86 | MDM2 (0.41) | MDM2GAAL3MBTL1IRAK4DRD2 | |
| SCHEMBL681668 | 0.86 | — | — | |
| SCHEMBL23366007 | 0.85 | MDM2 (0.41) | MDM2 | |
| SCHEMBL17827401 | 0.85 | MDM2 (0.41) | MDM2 | |
| SCHEMBL21501958 | 0.85 | MDM2 (0.41) | MDM2 | |
| SCHEMBL27089683 | 0.85 | MDM2 (0.41) | MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873288-B2 | Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873288-B2 | Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-16 | — | — | US | disclosed |
| US-11672803-B2 | Use of inhibitors of Brutons tyrosine kinase (Btk) | PHARMACYCLICS LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220249683-A1 | T-CELL DEPLETING THERAPIES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2022-08-11 | — | — | US | disclosed |
| US-20220177575-A1 | ANTI-CD117 ANTIBODIES AND USES THEREOF | Magenta Therapeutics, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-20220175946-A1 | CONDITIONING METHODS FOR GENE THERAPY | REGENERON PHARMACEUTICALS, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220177577-A1 | ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-20220175944-A1 | ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-20210371524-A1 | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210155601-A1 | INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-27 | — | — | US | disclosed |
| US-20150299171-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2015-10-22 | — | — | US | disclosed |
| US-9107924-B2 | Inhibitors of Bruton'S tyrosine kinase for the treatment of solid tumors | PHARMACYCLICS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-8883435-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140194446-A1 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | PHARMACYCLICS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140079690-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20130178483-A1 | Methods and Compositions for Inhibition of Bone Resorption | PHARMACYCLICS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130005745-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC (US) | 2013-01-03 | — | — | US | disclosed |
| US-20120283277-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120165328-A1 | INHIBITORS OF B LYMPHOCYTE KINASE | PHARMACYCLICS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20100254905-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177575-A1 | ANTI-CD117 ANTIBODIES AND USES THEREOF | MYADM, SIGLEC7, ITGB7 | MDM2 3538/4885GAA 779/4885L3MBTL1 1997/4885 |
| US-20120165328-A1 | INHIBITORS OF B LYMPHOCYTE KINASE | BLK, DCK, LTK | MDM2 2038/4885GAA 3067/4885L3MBTL1 426/4885 |
| US-20120283277-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | MDM2 2449/4885GAA 1422/4885L3MBTL1 1139/4885 |
| US-20210371524-A1 | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF | CD44, LY6K, CD2 | MDM2 4261/4885GAA 351/4885L3MBTL1 3010/4885 |
| US-11873288-B2 | Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) | FAAH, FAAH2, EPHX2 | MDM2 3366/4885GAA 2254/4885L3MBTL1 4420/4885 |
| US-20220175944-A1 | ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | ITGB7, KIT, CD2 | MDM2 3796/4885GAA 494/4885L3MBTL1 4623/4885 |
| US-20140194446-A1 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | BTK, SYK, LYN | MDM2 3019/4885GAA 2903/4885L3MBTL1 1753/4885 |
| US-20210155601-A1 | INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) | FAAH, FAAH2, EPHX2 | MDM2 3366/4885GAA 2254/4885L3MBTL1 4420/4885 |
| US-20130178483-A1 | Methods and Compositions for Inhibition of Bone Resorption | BTK, CTTN, BMX | MDM2 2635/4885GAA 1661/4885L3MBTL1 2628/4885 |
| US-20220177577-A1 | ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF | SIGLEC7, FUT7, ITGB7 | MDM2 4518/4885GAA 317/4885L3MBTL1 4643/4885 |
| US-20150299171-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | MDM2 1736/4885GAA 2422/4885L3MBTL1 1900/4885 |
| US-20100254905-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | MDM2 2520/4885GAA 1904/4885L3MBTL1 492/4885 |
| US-11672803-B2 | Use of inhibitors of Brutons tyrosine kinase (Btk) | BTK, LYN, SYK | MDM2 2964/4885GAA 3013/4885L3MBTL1 1517/4885 |
| US-20130005745-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | MDM2 2449/4885GAA 1422/4885L3MBTL1 1139/4885 |
| US-20220175946-A1 | CONDITIONING METHODS FOR GENE THERAPY | CD74, CD2, CD44 | MDM2 4310/4885GAA 210/4885L3MBTL1 1031/4885 |
| US-20140079690-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | MDM2 1656/4885GAA 1771/4885L3MBTL1 345/4885 |
| US-20220249683-A1 | T-CELL DEPLETING THERAPIES | CD2, CD4, CD22 | MDM2 3679/4885GAA 3378/4885L3MBTL1 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.